M. Hoeper (Hannover, Germany), S. Gaine (Dublin, Ireland)
Combination therapy with sotatercept analog RAP-011 is superior to sildenafil alone in severe experimental PAH and RAP-011 benefits persist after treatment cessation
S. JOSHI (Cambridge, United States of America), J. Liu (Cambridge, United States of America), R. Pearsall (Cambridge, United States of America), P. Andre (Cambridge, United States of America), G. Li (Cambridge, United States of America), R. Kumar (Cambridge, United States of America)
|     |
Long-term outcomes with initial triple oral therapy in pulmonary arterial hypertension (PAH): Insights from TRITON
O. Sitbon (Le Kremlin Bicêtre, France), N. Galiè (Bologna, Italy), M. Doelberg (Allschwil, Switzerland), J. Gibbs (London, United Kingdom), M. Hoeper (Hannover, Germany), M. Stefani (Allschwil, Switzerland), S. Mathai (Baltimore, United States of America), V. Mclaughlin (Ann Arbor, United States of America), L. Perchenet (Allschwil, Switzerland), G. Simonneau (Le Kremlin Bicêtre, France), K. Chin (Dallas, United States of America)
| |
Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2)
A. Boucly (Le Kremlin Bicètre, France), A. Baron (Le Kremlin Bicètre, France), L. Savale (Le Kremlin Bicètre, France), X. Jaïs (Le Kremlin Bicètre, France), F. Picard (Bordeaux, France), V. Cottin (Lyon, France), E. Bergot (Caen, France), C. Dauphin (Clermont-Ferrand, France), A. Bourdin (Montpelliernt-Ferrand, France), A. Chaouat (Nancy, France), P. Roblot (Dijon, France), C. Chabanne (Rennes, France), G. Prévot (Toulouse, France), L. Bertoletti (Saint-Etienne, France), D. Montani (Le Kremlin Bicètre, France), G. Simonneau (Le Kremlin Bicètre, France), M. Humbert (Le Kremlin Bicètre, France), O. Sitbon (Le Kremlin Bicètre, France)
| |
REPAIR: long-term effects of macitentan on the right ventricle (RV) in pulmonary arterial hypertension (PAH)
D. Kiely (Sheffield (South Yorkshire), United Kingdom), E. Cottreel (Allschwil, Switzerland), N. Galiè (Bologna, Italy), J. Marcus (Amsterdam, Netherlands), A. Peacock (Glasgow, United Kingdom), S. Rosenkranz (Cologne, Germany), A. Swift (Sheffield, United Kingdom), A. Tawakol (Boston, United States of America), A. Torbicki (Otwock, Poland), A. Vonk Noordegraaf (Amsterdam, Netherlands), G. Wetherill (Allschwil, Switzerland), R. Channick (Los Angeles, United States of America)
| |
Standardised exercise training is feasible, safe and effective in pulmonary arterial and chronic thromboembolic pulmonary hypertension - results from a large European multicentre randomised controlled trial
E. Grünig (Heidelberg, Germany), A. Mackenzie (Glasgow, United Kingdom), A. Peackock (Glasgow, United Kingdom), C. Eichstaedt (Heidelberg, Germany), N. Benjamin (Heidelberg, Germany), R. Nechwatal (Heidelberg, Germany), S. Ulrich (Zurich, Switzerland), S. Saxer (Zurich, Switzerland), M. Bussotti (Milan, Italy), M. Sommaruga (Milan, Italy), S. Ghio (Pavia, Italy), L. Gumbiene (Vilnius, Lithuania), E. Paleviciute (Vilnius, Lithuania), E. Jureviciene (Vilnius, Lithuania), A. Cittadini (Salerno, Italy), A. Stanziola (Naples, Italy), A. Marra (Naples, Italy), G. Kovacs (Graz, Austria), H. Olschewski (Graz, Austria), J. Barberà (Barcelona, Spain), I. Blanco (Barcelona, Spain), M. Spruit (Maastricht, Netherlands), F. Franssen (Horn, Netherlands), A. Vonk Noordegraaf (Amsterdam, Netherlands), A. Reis (Porto, Portugal), M. Santos (Porto, Portugal), S. Goncalves Viamonte (Porto, Portugal), H. Demeyer (Leuven, Belgium), M. Delcroix (Leuven, Belgium), E. Bossone (Naples, Italy), M. Johnson (Glasgow, United Kingdom)
| |
EmPHasis-10 health-related quality of life score predicts outcomes in patients with idiopathic and connective tissue disease-associated pulmonary arterial hypertension: results from a UK multi-centre study
R. Lewis (Sheffield (South Yorkshire), United Kingdom), I. Armstrong (Sheffield (South Yorkshire), United Kingdom), C. Bergbaum (London, United Kingdom), M. Brewis (Glasgow, United Kingdom), J. Cannon (Cambridge, United Kingdom), A. Charalampopoulos (Sheffield (South Yorkshire), United Kingdom), A. Church (Glasgow, United Kingdom), J. Coghlan (London, United Kingdom), R. Davies (London, United Kingdom), K. Dimopoulos (London, United Kingdom), C. Elliot (Sheffield, United Kingdom), J. Gibbs (London, United Kingdom), W. Gin-Sing (London, United Kingdom), G. Haji (London, United Kingdom), A. Hameed (Sheffield (South Yorkshire), United Kingdom), L. Howard (London, United Kingdom), M. Johnson (Glasgow, United Kingdom), A. Kempny (London, United Kingdom), D. Kiely (Sheffield (South Yorkshire), United Kingdom), F. Lo Giudice (Manchester, United Kingdom), C. Mccabe (London, United Kingdom), O. Peleyeju (London, United Kingdom), J. Pepke-Zaba (Cambridge, United Kingdom), G. Polwarth (Cambridge, United Kingdom), L. Price (London, United Kingdom), I. Sabroe (Sheffield (South Yorkshire), United Kingdom), B. Schreiber (London, United Kingdom), K. Sheares (Cambridge, United Kingdom), D. Taboada (Cambridge, United Kingdom), A. Thompson (Sheffield (South Yorkshire), United Kingdom), M. Toshner (Cambridge, United Kingdom), I. Wanjiku (London, United Kingdom), S. Wort (London, United Kingdom), J. Yorke (Manchester, United Kingdom), R. Condliffe (Sheffield (South Yorkshire), United Kingdom)
| |
In-depth risk stratification in pulmonary arterial hypertension
A. Yogeswaran (Giessen, Germany), K. Tello (Giessen, Germany), N. Sommer (Giessen, Germany), H. Ghofrani (Giessen, Germany), W. Seeger (Giessen, Germany), M. Richter (Giessen, Germany), H. Gall (Giessen, Germany)
| |